Related Articles
Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma
Effects of complement and serum IgG on rituximab‑dependent natural killer cell‑mediated cytotoxicity against Raji cells
Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma
Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma